Testing azacitidine and decitabine for bone marrow cancers
Treatments studied
Part of Blood & lymphatic clinical trials.
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MDS, or an MDS/MPS overlap condition (like certain CMML or RARS-T types).
- Your doctor believes you may respond to these medicines based on past evidence—often because your disease has symptoms like anemia or low platelets, or you need blood/platelet transfusions.
- Your MDS risk level is not the highest-risk group (high/very high or intermediate-2 and above).
- You have enough strength to do study tasks (Karnofsky performance score 60% or higher).
- Your liver tests are not too high (AST/ALT under 3× normal; bilirubin under 1.5× normal).
- You can sign consent and do required study visits and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
This trial tests whether adding high-dose vitamin C (ascorbate) to a standard chemotherapy drug (azacitidine) helps people with higher-risk myelodysplastic syndrome (MDS). It is for those who have had little or no prior treatment for MDS.
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
This Phase 1 trial tests whether SX-682 given alone or with decitabine can treat myelodysplastic syndrome (MDS) that has not responded well to prior therapy. It also studies safety and the best dose, which may help people who have limited treatment options.
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.